Context Therapeutics Inc., a biopharmaceutical company, develops products for the treatment of solid tumors. Its lead program candidate is CTIM-76, an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. The company has a collaboration and licensing agreement with Integral Molecular, Inc. for the development of a CLDN6 bispecific monoclonal antibody for cancer therapy. The company was incorporated in 2015 and is headquartered in Philadelphia, Pennsylvania. Show more

Location: 2001 Market Street, Suite 200, Philadelphia, PA, 19103, United States | Website: https://www.contexttherapeutics.com | Industry: Biotechnology | Sector: Healthcare

Market Cap

58.77M

52 Wk Range

$0.49 - $2.75

Previous Close

$0.66

Open

$0.67

Volume

190,168

Day Range

$0.62 - $0.68

Enterprise Value

-30.38M

Cash

89.35M

Avg Qtr Burn

-3.806M

Insider Ownership

2.33%

Institutional Own.

79.93%

Qtr Updated

03/31/25

Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
CT-95 Details Solid tumor/s	Phase 1 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
CTIM-76 Details Testicular cancer, Endometrial cancer, Ovarian cancer	Phase 1 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
ONA-XR Details Metastatic breast cancer to brain, ER+/HER2- breast cancer, Breast cancer, Cancer, Solid tumor/s	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
ONA-XR Details Breast cancer, Cancer, Solid tumor/s, Metastatic breast cancer to brain, ER+/HER2- breast cancer	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
ONA-XR Details Solid tumor/s, Cancer, Ovarian cancer, Endometrial cancer	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.